ALS Clinical Trails

[EDDIEKIRK]

<div>
Mexiletine - channeling ALS?

<div>
Posted by Michelle Pflumm, Ph.D.





<div style="margin-left:10px;">
<div class="ipsEmbeddedVideo " contenteditable="false"><div><iframe width="480" height="270" src="https://www.youtube.com/embed/hSvHSNs1f1o?feature=oembed" frameborder="0" allowfullscreen="true"></iframe></div>
Calming ALS nervesMexiletine may help protect the motor nerves from further damage by reducing the overactivity of sodium channels (blue) snaking through the CNS. Courtesy of Wellcome Images.

</div>
New medicines can take more than a decade to go from the laboratory to the clinic. But with many of their ALS patients facing 2-5 years to live, clinicians are rethinking the way that potential medicines are being pushed forward in the clinic. Adaptive clinical trial designs according to some experts might enable drugs to be evaluated more rapidly. And, futility studies may allow ineffective and unsafe medicines to be more quickly discarded.

Some researchers, however, hope to bring potentially life-changing treatments to people with ALS even faster by dusting off existing FDA-approved drugs from pharmacy shelves which target emerging key mechanisms of the disease.

One of these medicines, mexiletine, may help reduce the overactivity (hyperexcitability) of certain neurons in people with ALS, a potentially early step in the disease. The drug, suspect researchers, may therefore reduce further injury to the motor nerves slowing the progression of the disease.

Mexiletine could be of benefit in ALS, says University of Washington School of Medicine neuromuscular disease specialistMichael Weiss MD, principal investigator of the study. Hyperexcitability could be a very early event in the neurodegenerative process.

The phase II clinical trial is scheduled to begin sometime in early 2013.



Check out our podcast with UW neurologist Michael Weiss MD to learn more about mexiletine and its potential benefits for people with ALS.

<div><div>
<div>

</div></div>
</div>
Cliniciansfirst looked to mexiletine in the early 1990s to reduce muscle stiffness in people with a rare group of muscle diseases called myotonias. The drug, originally developed to regulate heart rhythms, is thought to shut the gate of inappropriately activated sodium channels - helping muscles relax more easily.

Mexiletine, recently put to the test in people with non-dystrophic myotonias, appears to reduce key signs of myotonia including muscle stiffness and muscle pain. The drug is quickly becoming routine practice for myotonia in people with these muscle diseases.

We showed that mexiletine worked. Its a really big deal, says University of Kansas Medical Center neuromuscular disease specialist Richard Barohn MD, leader of the study.

Mexiletine is now being evaluated as a potential treatment for muscle cramps in a growing number of conditions including in people with ALS.

We think the large [part of the] problem with muscle cramps is these persistent sodium channels, explains University of California - Davis School of Medicine neurologist Bjorn Oskarsson MD, principal investigator of the study. The axons are not working right.

Out of hyperdrive?

University of Massachusetts neurologist Robert Brown MD however suspects that mexiletine might do much moreforpeople with ALS. The drug might reduce the overactivity of sodium channels on certain neurons in the brain and spinal cord a potential cause or contributor to the damage that fuels the progression of ALS. The daily treatment of mexiletine according to Brown significantly extends the survival of a mouse model of the disease.




Quiet downMexiletine might reduce the flow of sodium ions (green) through neuronal channels (above) in the brain and spinal cord - helping to protect the motor nerves. Video: Courtesy of Vladimir Yarov-Yarovoy PhD, University of California Davis School of Medicine.


This overactivity, know as hyperexcitability, is suspected to be an early step in the disease according to studies led by King's College London's Kerry Mills PhD FRCP and Neuroscience Research Australias Steve Vucic PhD. Sodium channels that decorate certain neurons of the motor regions of the brain appear to be overactive in people with ALS. And, these changes may occur before the onset of symptoms according to a small study of people at high risk of developing the familial form of the disease.

Mexiletine therefore might not only protect the motor nerves from further damage; the drug might slow ALS even earlier in the disease course.

Now, US neurologists are gearing up to put mexiletine to the test in people with ALS to determine whether the drug can indeed slow down the disease.

The 16 week phase II clinical trial will take place at 10 Northeast ALS Consortium (NEALS) sites in the US including the University of Washington School of Medicine, University of Kansas Medical Center and Penn State University School of Medicine.

The main goal is to evaluate the safety and tolerability of mexiletine in people with ALS. Other measures include functional abilities (ALS FRS) and the frequency and severity of muscle cramps. 60 people with ALS are expected to participate.

Mexiletine is a drug we know a fair amount about, says University of Washington neuromuscular disease specialist Michael Weiss MD. Its a pretty safe medicine. Its been FDA-approved for almost two decades.

Patient Resources

A safety and tolerability study of mexiletine in patients with sporadic ALS. Contact

Mexiletine for the treatment of muscle cramps in ALS. Contact|ALS TDI|Website

References

Vucic, S and Kiernan, M.C. (2010) Upregulation of persistent sodium conductances in familial ALS. Journal of Neurology, Neurosurgery and Psychiatry 81(2), 222-227. Abstract | Full Text (Subscription Required)

Vucic, S., Nicholson, G.A. and Kiernan, M.C. (2008) Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 131, 1540-1550. Abstract | Full Text

Mills, K.R. and Nithi, K.A. (1997) Corticomotor threshold is reduced in early sporadic amyotrophic lateral sclerosis. Muscle and Nerve 20(9), 1137-1141. Abstract | Full Text (Subscription Required)

Kwieciski, H., Ryniewicz, B. and Ostrzycki, A. (1992) Treatment of myotonia with antiarrhythmic drugs. Acta Neurologica Scandinavica 86(4), 371-375. Abstract | Full Text (Subscription Required)

Further reading

Vucic, S., Ziemann, U., Eisen, A., Hallett, M. and Kiernan, M.C. (2012) Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. Journal of Neurology, Neurosurgery and Psychiatry doi:10.1136/jnnp2012-304019 Abstract | Full Text (Subscription Required)

Statland, J.M. et al. (2012) Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. Journal of the American Medical Association 308(13), 1357-1365. Abstract | Full Text (Subscription Required)

Kanai, K., Kuwabara, S., Arai, K., Sung, J.Y., Ogawara, K. and Hattori, T. (2003) Muscle cramp in Machado-Joseph disease: altered motor axonal excitability properties and mexiletine treatment. Brain 126, 965-973. Abstract | Full Text

</div>
</div>
Permalink
</div>